Raffles Medical Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Raffles Medical Group wird ein jährliches Gewinn- und Umsatzwachstum von 12.6% bzw. 4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 7.3% betragen.

Wichtige Informationen

12.6%

Wachstumsrate der Gewinne

10.9%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	19.0%
Wachstumsrate der Einnahmen	4.0%
Zukünftige Eigenkapitalrendite	7.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	02 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Raffles Medical Group (SGX:BSL) Is Reducing Its Dividend To SGD0.024

May 09

Raffles Medical Group's (SGX:BSL) Dividend Is Being Reduced To SGD0.024

Apr 25

Raffles Medical Group's (SGX:BSL) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 10

Estimating The Intrinsic Value Of Raffles Medical Group Ltd (SGX:BSL)

Nov 16

Raffles Medical Group (SGX:BSL) Is Doing The Right Things To Multiply Its Share Price

Nov 03

Is There An Opportunity With Raffles Medical Group Ltd's (SGX:BSL) 25% Undervaluation?

Oct 09

Is Raffles Medical Group (SGX:BSL) A Risky Investment?

Sep 26

The Return Trends At Raffles Medical Group (SGX:BSL) Look Promising

Sep 01

With EPS Growth And More, Raffles Medical Group (SGX:BSL) Makes An Interesting Case

Aug 20

Raffles Medical Group (SGX:BSL) Has Some Way To Go To Become A Multi-Bagger

Jun 01

Raffles Medical Group (SGX:BSL) Is Increasing Its Dividend To S$0.028

May 02

We Think Raffles Medical Group (SGX:BSL) Can Manage Its Debt With Ease

Apr 18

Slowing Rates Of Return At Raffles Medical Group (SGX:BSL) Leave Little Room For Excitement

Feb 21

Raffles Medical Group (SGX:BSL) Seems To Use Debt Rather Sparingly

Oct 14

Raffles Medical Group (SGX:BSL) Has Some Way To Go To Become A Multi-Bagger

Oct 02

At S$1.40, Is Raffles Medical Group Ltd (SGX:BSL) Worth Looking At Closely?

Sep 21

Here's Why I Think Raffles Medical Group (SGX:BSL) Is An Interesting Stock

Aug 12

Here's What's Concerning About Raffles Medical Group's (SGX:BSL) Returns On Capital

Jul 01

At S$1.08, Is It Time To Put Raffles Medical Group Ltd (SGX:BSL) On Your Watch List?

May 25

Does This Valuation Of Raffles Medical Group Ltd (SGX:BSL) Imply Investors Are Overpaying?

Apr 05

Gewinn- und Umsatzwachstumsprognosen

SGX:BSL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SGD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	821	83	106	123	5
12/31/2025	785	78	100	123	8
12/31/2024	741	69	-8	98	8
6/30/2024	703	61	72	97	N/A
3/31/2024	706	76	120	143	N/A
12/31/2023	708	90	167	189	N/A
9/30/2023	747	117	166	189	N/A
6/30/2023	786	144	165	188	N/A
3/31/2023	805	143	168	192	N/A
12/31/2022	825	143	171	196	N/A
9/30/2022	808	124	179	204	N/A
6/30/2022	791	104	188	212	N/A
3/31/2022	758	94	148	186	N/A
12/31/2021	725	84	107	160	N/A
9/30/2021	698	86	108	171	N/A
6/30/2021	671	88	109	181	N/A
3/31/2021	619	77	91	157	N/A
12/31/2020	568	66	73	133	N/A
9/30/2020	541	60	42	121	N/A
6/30/2020	508	50	23	105	N/A
3/31/2020	514	55	21	107	N/A
12/31/2019	522	60	13	111	N/A
9/30/2019	514	63	16	93	N/A
6/30/2019	504	66	28	92	N/A
3/31/2019	497	69	35	89	N/A
12/31/2018	489	71	62	94	N/A
9/30/2018	484	71	63	88	N/A
6/30/2018	483	71	57	81	N/A
3/31/2018	483	71	N/A	88	N/A
12/31/2017	478	71	N/A	83	N/A
9/30/2017	473	70	N/A	81	N/A
6/30/2017	473	70	N/A	65	N/A
3/31/2017	472	70	N/A	63	N/A
12/31/2016	474	70	N/A	79	N/A
9/30/2016	470	71	N/A	83	N/A
6/30/2016	452	71	N/A	92	N/A
3/31/2016	432	70	N/A	91	N/A
12/31/2015	411	69	N/A	73	N/A
9/30/2015	396	69	N/A	86	N/A
6/30/2015	389	68	N/A	79	N/A
3/31/2015	382	68	N/A	94	N/A
12/31/2014	375	68	N/A	93	N/A
9/30/2014	363	89	N/A	66	N/A
6/30/2014	353	87	N/A	83	N/A
3/31/2014	347	86	N/A	71	N/A
12/31/2013	341	85	N/A	71	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BSLDas prognostizierte Gewinnwachstum (12.6% pro Jahr) liegt über der Sparquote (2.2%).

Ertrag vs. Markt: BSLDie Erträge des Unternehmens (12.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SG (11.4% pro Jahr).

Hohe Wachstumserträge: BSLDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BSLDie Einnahmen des Unternehmens (4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SG (3.8% pro Jahr).

Hohe Wachstumseinnahmen: BSLDie Einnahmen des Unternehmens (4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BSLDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (7.3%).

Raffles Medical Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 12% to S$1.14

Consensus EPS estimates fall by 21%

Price target increased by 8.1% to S$1.72

Price target increased to S$1.52

Price target decreased to S$1.39

Price target decreased to S$1.39

Recent updates

Executive Chairman & CEO recently bought S$1.3m worth of stock

Executive Chairman & CEO recently bought S$979k worth of stock

Executive Chairman & CEO recently bought S$1.5m worth of stock

Executive Chairman & CEO recently bought S$700k worth of stock

New minor risk - Dividend sustainability

Executive Chairman & CEO recently bought S$1.3m worth of stock

First half 2024 earnings released: EPS: S$0.017 (vs S$0.032 in 1H 2023)

Executive Chairman & CEO recently bought S$1.5m worth of stock

Raffles Medical Group Ltd to Report First Half, 2024 Results on Jul 29, 2024

Raffles Medical Group (SGX:BSL) Is Reducing Its Dividend To SGD0.024

Executive Chairman & CEO recently bought S$500k worth of stock

Upcoming dividend of S$0.024 per share

Raffles Medical Group Ltd Approves One-Tier Tax Exempt Final Dividend for the Year Ended 31 December 2023, Payable on May 23, 2024

Raffles Medical Group's (SGX:BSL) Dividend Is Being Reduced To SGD0.024

Raffles Medical Group's (SGX:BSL) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2023 earnings: EPS misses analyst expectations

Now 20% undervalued

Raffles Medical Group Ltd Proposes Final Dividend for the Year Ended 31 December 2023, Payable on May 23, 2024

Price target decreased by 12% to S$1.14

Consensus EPS estimates fall by 21%

Executive Chairman & CEO recently bought S$3.6m worth of stock

Dividend of S$0.024 announced

Raffles Medical Group Ltd, Annual General Meeting, Apr 26, 2024

Estimating The Intrinsic Value Of Raffles Medical Group Ltd (SGX:BSL)

Investor sentiment deteriorates as stock falls 15%

Raffles Medical Group (SGX:BSL) Is Doing The Right Things To Multiply Its Share Price

Here's Why Raffles Medical Group (SGX:BSL) Has Caught The Eye Of Investors

Raffles Medical Group Ltd Announces Resignation of Soo Yu-Han Jessica as Joint Company Secretary, Effective 8 August 2023

High number of new directors

First half 2023 earnings released: EPS: S$0.032 (vs S$0.032 in 1H 2022)

Raffles Medical Group Ltd Announces Appointment of Lu Liangjian as Non-Executive and Non-Independent Director

The Return Trends At Raffles Medical Group (SGX:BSL) Look Promising

Raffles Medical Group Ltd to Report First Half, 2023 Results on Jul 31, 2023

Raffles Medical Group (SGX:BSL) Could Easily Take On More Debt

A Look At The Fair Value Of Raffles Medical Group Ltd (SGX:BSL)

Is Now The Time To Put Raffles Medical Group (SGX:BSL) On Your Watchlist?

Upcoming dividend of S$0.038 per share at 2.6% yield

Raffles Medical Group (SGX:BSL) Is Increasing Its Dividend To SGD0.038

Full year 2022 earnings: Revenues in line with analyst expectations

Raffles Medical Group (SGX:BSL) Might Have The Makings Of A Multi-Bagger

Price target increased by 8.1% to S$1.72

Full year 2022 earnings: EPS exceeds analyst expectations

Estimating The Intrinsic Value Of Raffles Medical Group Ltd (SGX:BSL)

Raffles Medical Group Ltd to Report Fiscal Year 2022 Results on Feb 27, 2023

Returns At Raffles Medical Group (SGX:BSL) Are On The Way Up

Do Raffles Medical Group's (SGX:BSL) Earnings Warrant Your Attention?

Now 21% undervalued

Is There An Opportunity With Raffles Medical Group Ltd's (SGX:BSL) 25% Undervaluation?

Is Raffles Medical Group (SGX:BSL) A Risky Investment?

Now 21% undervalued

The Return Trends At Raffles Medical Group (SGX:BSL) Look Promising

With EPS Growth And More, Raffles Medical Group (SGX:BSL) Makes An Interesting Case

Now 20% undervalued

Investor sentiment improved over the past week

Price target increased to S$1.52

Executive Chairman & CEO recently bought S$63k worth of stock

First half 2022 earnings released

Raffles Medical Group Ltd to Report First Half, 2022 Results on Aug 01, 2022

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Raffles Medical Group (SGX:BSL) Has Some Way To Go To Become A Multi-Bagger

Raffles Medical Group Ltd Approves Final Dividend for the Year Ended 31 December 2021

Raffles Medical Group Ltd Approves Final Dividend for the Year Ended 31 December 2021

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of S$0.028 per share

Raffles Medical Group (SGX:BSL) Is Increasing Its Dividend To S$0.028

Price target decreased to S$1.39

Raffles Medical Group Ltd Approves the Ordinary (One-Tier Tax Exempt) Core Dividend for the Financial Year Ended December 31, 2021, Payable on May 19, 2022